Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226427 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A Phase 1 study of Platinum-resistant Ovarian Cancer, sponsored by Stemline Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07226427: Recruiting Phase 1 study of Platinum-resistant Ovarian Cancer, sponsored by Stemline Therapeutics.
NCT07226427 is a Phase 1 study of Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Stemline Therapeutics. The registered enrollment target is 100 participants, below the 180-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226427, a Phase 1 study of Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Stemline Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Conditions Studied
Interventions
- DRUG MEN2501
Study Locations (1)
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11 |
| Est. Completion | 2028-06-02 |
| Phase | Phase 1 |
What NCT07226427 shows while recruiting
NCT07226427 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 180-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which MEN2501 is the first listed.
NCT07226427 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07226427 about?
NCT07226427 is a clinical study titled "A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer". This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
What is the current status of trial NCT07226427?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-11. Estimated completion is 2028-06-02.
What conditions does trial NCT07226427 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT07226427?
The interventions under investigation include: MEN2501 (DRUG).
Who is sponsoring clinical trial NCT07226427?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226427 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226427's enrollment target sits among peer trials
100 10th of 17 higher than 8 of 17 other Platinum-resistant Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Platinum-resistant Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RECRUITING · Phase 1
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia